Strategic use of conformational bias and structure based design to identify potent JAK3 inhibitors with improved selectivity against the JAK family and the kinome.

Using a structure based design approach we have identified a series of indazole substituted pyrrolopyrazines, which are potent inhibitors of JAK3. Intramolecular electronic repulsion was used as a strategy to induce a strong conformational bias within the ligand. Compounds bearing this conformation participated in a favorable hydrophobic interaction with a cysteine residue in the JAK3 binding pocket, which imparted high selectivity versus the kinome and improved selectivity within the JAK family.

[1]  S. Buchwald,et al.  Copper-diamine-catalyzed N-arylation of pyrroles, pyrazoles, indazoles, imidazoles, and triazoles. , 2004, The Journal of organic chemistry.

[2]  Eric Vangrevelinghe,et al.  Identification of a potent Janus kinase 3 inhibitor with high selectivity within the Janus kinase family. , 2011, Journal of medicinal chemistry.

[3]  Xin Xu,et al.  Selective functional inhibition of JAK-3 is sufficient for efficacy in collagen-induced arthritis in mice. , 2010, Arthritis and rheumatism.

[4]  J. O’Shea,et al.  A new modality for immunosuppression: targeting the JAK/STAT pathway , 2004, Nature Reviews Drug Discovery.

[5]  W. Leonard,et al.  Mutation of Jak3 in a Patient with SCID: Essential Role of Jak3 in Lymphoid Development , 1995, Science.

[6]  N. K. Williams,et al.  Dissecting specificity in the Janus kinases: the structures of JAK-specific inhibitors complexed to the JAK1 and JAK2 protein tyrosine kinase domains. , 2009, Journal of molecular biology.

[7]  A. Gottlieb,et al.  Preliminary clinical activity of a topical JAK1/2 inhibitor in the treatment of psoriasis. , 2012, Journal of the American Academy of Dermatology.

[8]  W. Pitts,et al.  Chapter 12 Advances in the Discovery of Small Molecule JAK3 Inhibitors , 2009 .

[9]  David Gruben,et al.  The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: Results of a double-blind, placebo-controlled phase IIa trial of three dosage levels of CP-690,550 versus placebo. , 2009, Arthritis and rheumatism.

[10]  L. Wodicka,et al.  A small molecule–kinase interaction map for clinical kinase inhibitors , 2005, Nature Biotechnology.

[11]  L. Wilson.  Recent patents in the discovery of small molecule inhibitors of JAK3 , 2010, Expert opinion on therapeutic patents.

[12]  J. Johnston,et al.  Mutations of Jak-3 gene in patients with autosomal severe combined immune deficiency (SCID) , 1995, Nature.

[13]  J. O’Shea,et al.  Janus kinases in immune cell signaling , 2009, Immunological reviews.

[14]  T. Boggon,et al.  Crystal structure of the Jak3 kinase domain in complex with a staurosporine analog. , 2005, Blood.

[15]  Stephen F Martin,et al.  Preorganization in biological systems: Are conformational constraints worth the energy? , 2007 .

[16]  M. Hines,et al.  Discovery of CP-690,550: a potent and selective Janus kinase (JAK) inhibitor for the treatment of autoimmune diseases and organ transplant rejection. , 2010, Journal of medicinal chemistry.

[17]  W. L. Jorgensen,et al.  Energetics of displacing water molecules from protein binding sites: consequences for ligand optimization. , 2009, Journal of the American Chemical Society.

[18]  J. O’Shea,et al.  Therapeutic targeting of Janus kinases , 2008, Immunological reviews.

[19]  I. Behrmann,et al.  Jak1 has a dominant role over Jak3 in signal transduction through γc-containing cytokine receptors. , 2011, Chemistry & biology.

[20]  Alam Jahangir,et al.  3-Amido pyrrolopyrazine JAK kinase inhibitors: development of a JAK3 vs JAK1 selective inhibitor and evaluation in cellular and in vivo models. , 2013, Journal of medicinal chemistry.

[21]  Jian Wang,et al.  Janus kinase 2 inhibitors. Synthesis and characterization of a novel polycyclic azaindole. , 2009, Journal of medicinal chemistry.

[22]  J. O’Shea,et al.  Selectivity and therapeutic inhibition of kinases: to be or not to be? , 2009, Nature Immunology.

[23]  Jude Dunne,et al.  Comparison of on-chip and off-chip microfluidic kinase assay formats. , 2004, Assay and drug development technologies.

[24]  J. Kremer,et al.  Inhibition of JAK kinases in patients with rheumatoid arthritis: scientific rationale and clinical outcomes. , 2010, Best practice & research. Clinical rheumatology.